Loading...

Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma

Following the discovery that nearly half of all cutaneous melanomas harbour a mutation in the BRAF gene, molecular targeted kinase inhibitors have been developed for the treatment of metastatic melanoma and have dramatically improved outcomes for those patients with BRAF mutant disease, achieving hi...

Full description

Saved in:
Bibliographic Details
Published in:Ther Adv Med Oncol
Main Authors: Welsh, Sarah J., Corrie, Pippa G.
Format: Artigo
Language:Inglês
Published: SAGE Publications 2015
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4346212/
https://ncbi.nlm.nih.gov/pubmed/25755684
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834014566428
Tags: Add Tag
No Tags, Be the first to tag this record!